OXBRYTA Sales Forecast, and Market Size Analysis – 2034
Description
Key Factors Driving OXBRYTA Growth
1. Novel disease-modifying mechanism (HbS polymerization inhibition)
OXBRYTA is a first-in-class hemoglobin S (HbS) polymerization inhibitor, directly targeting the root cause of sickling rather than downstream symptoms.
This differentiated mechanism positioned it as a disease-modifying therapy, unlike supportive treatments such as hydroxyurea.
Impact:
Strong scientific rationale drove rapid physician interest and early adoption, especially in patients with chronic anemia.
2. Strong hemoglobin improvement (key clinical differentiator)
In the Phase III HOPE trial,
Hemoglobin improvement is strongly associated with reduced hemolysis and anemia →
This became the primary value proposition, differentiating OXBRYTA from VOC-focused drugs like ADAKVEO.
3. Oral, once-daily therapy improving compliance
OXBRYTA is an oral, once-daily therapy, unlike infusion-based biologics.
Impact:
Easier administration improved patient adherence and real-world uptake, particularly in chronic use settings.
Enabled broader use beyond specialized infusion centers.
4. Broad label expansion (pediatric + combination use)
Initially approved in 2019 (≥12 years) and expanded in 2021 to patients ≥4 years.
Clinical trials allowed concomitant hydroxyurea use (~65% of patients).
Impact:
Expanded label significantly increased the addressable patient population, including pediatric patients.
Flexibility for combination therapy supported higher prescription volumes.
5. Strong commercial growth and revenue ramp-up
OXBRYTA generated approximately USD 328 million in global revenue in 2023.
Pfizer’s acquisition of Global Blood Therapeutics (~USD 5.4 billion) underscores expectations of high commercial potential.
Impact:
Demonstrated strong commercial traction post-launch (2019–2023), driven by:
In August 2025, Pfizer released positive data from the Phase III THRIVE-131 study for inclacumab, an investigational P-selectin inhibitor aimed at reducing vaso-occlusive crises (VOCs) in SCD patients.
“OXBRYTA Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of OXBRYTA for approved indication like Sickle cell anaemia in the 7MM. A detailed picture of OXBRYTA’s existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the OXBRYTA for approved indications. The OXBRYTA market report provides insights about OXBRYTA’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current OXBRYTA performance, future market assessments inclusive of the OXBRYTA market forecast analysis for approved indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of OXBRYTA sales forecasts, along with factors driving its market.
OXBRYTA Drug Summary
OXBRYTA is an oral once-daily prescription medication developed by Global Blood Therapeutics (now part of Pfizer), FDA-approved in 2019 under accelerated approval for adults and pediatric patients 12 years and older (later expanded to age 4 in some regions) with sickle cell disease (SCD) to treat hemolytic anemia by increasing hemoglobin levels. As a small-molecule hemoglobin S polymerization inhibitor, voxelotor binds directly to hemoglobin to enhance its oxygen affinity, preventing the formation of rigid sickle-shaped polymers under deoxygenated conditions, thereby maintaining red blood cell flexibility, reducing hemolysis, and improving oxygen delivery. It is available as 300 mg tablets or film-coated 500 mg tablets, dosed at 1500 mg daily (three 500 mg tablets or five 300 mg tablets) for adults and weight-based for pediatrics, taken with or without food but with consideration for its CYP3A4 inhibition potentially affecting other drugs; common side effects include diarrhea, headache, nausea, fatigue, rash, fever, and abdominal pain. The report provides OXBRYTA’s sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the OXBRYTA Market Report
The report provides insights into:
A comprehensive product overview including the OXBRYTA MoA, description, dosage and administration, research and development activities in approved indication like Sickle cell anaemia.
Elaborated details on OXBRYTA regulatory milestones and other development activities have been provided in OXBRYTA market report.
The report also highlights OXBRYTA‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.
The OXBRYTA market report also covers the patents information, generic entry and impact on cost cut.
The OXBRYTA market report contains current and forecasted OXBRYTA sales for approved indications till 2034.
Comprehensive coverage of the late-stage emerging therapies for respective indications.
The OXBRYTA market report also features the SWOT analysis with analyst views for OXBRYTA in approved indications.
Methodology
The OXBRYTA market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
OXBRYTA Analytical Perspective by DelveInsight
In-depth OXBRYTA Market Assessment
This OXBRYTA sales market forecast report provides a detailed market assessment of OXBRYTA for approved indication like Sickle cell anaemia in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted OXBRYTA sales data uptil 2034.
OXBRYTA Clinical Assessment
The OXBRYTA market report provides the clinical trials information of OXBRYTA for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.
OXBRYTA Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
OXBRYTA Market Potential & Revenue Forecast
Projected market size for the OXBRYTA and its key indications
Estimated OXBRYTA sales potential (OXBRYTA peak sales forecasts)
OXBRYTA Pricing strategies and reimbursement landscape
OXBRYTA Competitive Intelligence
Number of competing drugs in development (pipeline analysis)
OXBRYTA Market positioning compared to existing treatments
OXBRYTA Strengths & weaknesses relative to competitors
OXBRYTA Regulatory & Commercial Milestones
OXBRYTA Key regulatory approvals & expected launch timelines
Commercial partnerships, licensing deals, and M&A activity
OXBRYTA Clinical Differentiation
OXBRYTA Efficacy & safety advantages over existing drugs
OXBRYTA Unique selling points
OXBRYTA Market Report Highlights
In the coming years, the OXBRYTA market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
The OXBRYTA companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence OXBRYTA’s dominance.
Other emerging products for Sickle cell anaemia are expected to give tough market competition to OXBRYTA and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of OXBRYTA in approved indications.
Analyse OXBRYTA cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
Our in-depth analysis of the forecasted OXBRYTA sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of OXBRYTA in approved indications.
Key Questions
What is the class of therapy, route of administration and mechanism of action of OXBRYTA? How strong is OXBRYTA’s clinical and commercial performance?
What is OXBRYTA’s clinical trial status in each individual indications such as Sickle cell anaemia and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the OXBRYTA Manufacturers?
What are the key designations that have been granted to OXBRYTA for approved indications? How are they going to impact OXBRYTA’s penetration in various geographies?
What is the current and forecasted OXBRYTA market scenario for approved indications? What are the key assumptions behind the forecast?
What are the current and forecasted sales of OXBRYTA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What are the other emerging products available and how are these giving competition to OXBRYTA for approved indications?
Which are the late-stage emerging therapies under development for the treatment of approved indications?
How cost-effective is OXBRYTA? What is the duration of therapy and what are the geographical variations in cost per patient?
1. Novel disease-modifying mechanism (HbS polymerization inhibition)
OXBRYTA is a first-in-class hemoglobin S (HbS) polymerization inhibitor, directly targeting the root cause of sickling rather than downstream symptoms.
This differentiated mechanism positioned it as a disease-modifying therapy, unlike supportive treatments such as hydroxyurea.
Impact:
Strong scientific rationale drove rapid physician interest and early adoption, especially in patients with chronic anemia.
2. Strong hemoglobin improvement (key clinical differentiator)
In the Phase III HOPE trial,
- 51.1% of patients achieved >1 g/dL hemoglobin increase vs 6.5% placebo (p<0.001)
- Mean Hb increase was +1.1 g/dL vs −0.1 g/dL (placebo)
Hemoglobin improvement is strongly associated with reduced hemolysis and anemia →
This became the primary value proposition, differentiating OXBRYTA from VOC-focused drugs like ADAKVEO.
3. Oral, once-daily therapy improving compliance
OXBRYTA is an oral, once-daily therapy, unlike infusion-based biologics.
Impact:
Easier administration improved patient adherence and real-world uptake, particularly in chronic use settings.
Enabled broader use beyond specialized infusion centers.
4. Broad label expansion (pediatric + combination use)
Initially approved in 2019 (≥12 years) and expanded in 2021 to patients ≥4 years.
Clinical trials allowed concomitant hydroxyurea use (~65% of patients).
Impact:
Expanded label significantly increased the addressable patient population, including pediatric patients.
Flexibility for combination therapy supported higher prescription volumes.
5. Strong commercial growth and revenue ramp-up
OXBRYTA generated approximately USD 328 million in global revenue in 2023.
Pfizer’s acquisition of Global Blood Therapeutics (~USD 5.4 billion) underscores expectations of high commercial potential.
Impact:
Demonstrated strong commercial traction post-launch (2019–2023), driven by:
- Rapid uptake in US
- Expansion into global markets
In August 2025, Pfizer released positive data from the Phase III THRIVE-131 study for inclacumab, an investigational P-selectin inhibitor aimed at reducing vaso-occlusive crises (VOCs) in SCD patients.
“OXBRYTA Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of OXBRYTA for approved indication like Sickle cell anaemia in the 7MM. A detailed picture of OXBRYTA’s existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the OXBRYTA for approved indications. The OXBRYTA market report provides insights about OXBRYTA’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current OXBRYTA performance, future market assessments inclusive of the OXBRYTA market forecast analysis for approved indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of OXBRYTA sales forecasts, along with factors driving its market.
OXBRYTA Drug Summary
OXBRYTA is an oral once-daily prescription medication developed by Global Blood Therapeutics (now part of Pfizer), FDA-approved in 2019 under accelerated approval for adults and pediatric patients 12 years and older (later expanded to age 4 in some regions) with sickle cell disease (SCD) to treat hemolytic anemia by increasing hemoglobin levels. As a small-molecule hemoglobin S polymerization inhibitor, voxelotor binds directly to hemoglobin to enhance its oxygen affinity, preventing the formation of rigid sickle-shaped polymers under deoxygenated conditions, thereby maintaining red blood cell flexibility, reducing hemolysis, and improving oxygen delivery. It is available as 300 mg tablets or film-coated 500 mg tablets, dosed at 1500 mg daily (three 500 mg tablets or five 300 mg tablets) for adults and weight-based for pediatrics, taken with or without food but with consideration for its CYP3A4 inhibition potentially affecting other drugs; common side effects include diarrhea, headache, nausea, fatigue, rash, fever, and abdominal pain. The report provides OXBRYTA’s sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the OXBRYTA Market Report
The report provides insights into:
A comprehensive product overview including the OXBRYTA MoA, description, dosage and administration, research and development activities in approved indication like Sickle cell anaemia.
Elaborated details on OXBRYTA regulatory milestones and other development activities have been provided in OXBRYTA market report.
The report also highlights OXBRYTA‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.
The OXBRYTA market report also covers the patents information, generic entry and impact on cost cut.
The OXBRYTA market report contains current and forecasted OXBRYTA sales for approved indications till 2034.
Comprehensive coverage of the late-stage emerging therapies for respective indications.
The OXBRYTA market report also features the SWOT analysis with analyst views for OXBRYTA in approved indications.
Methodology
The OXBRYTA market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
OXBRYTA Analytical Perspective by DelveInsight
In-depth OXBRYTA Market Assessment
This OXBRYTA sales market forecast report provides a detailed market assessment of OXBRYTA for approved indication like Sickle cell anaemia in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted OXBRYTA sales data uptil 2034.
OXBRYTA Clinical Assessment
The OXBRYTA market report provides the clinical trials information of OXBRYTA for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.
OXBRYTA Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
OXBRYTA Market Potential & Revenue Forecast
Projected market size for the OXBRYTA and its key indications
Estimated OXBRYTA sales potential (OXBRYTA peak sales forecasts)
OXBRYTA Pricing strategies and reimbursement landscape
OXBRYTA Competitive Intelligence
Number of competing drugs in development (pipeline analysis)
OXBRYTA Market positioning compared to existing treatments
OXBRYTA Strengths & weaknesses relative to competitors
OXBRYTA Regulatory & Commercial Milestones
OXBRYTA Key regulatory approvals & expected launch timelines
Commercial partnerships, licensing deals, and M&A activity
OXBRYTA Clinical Differentiation
OXBRYTA Efficacy & safety advantages over existing drugs
OXBRYTA Unique selling points
OXBRYTA Market Report Highlights
In the coming years, the OXBRYTA market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
The OXBRYTA companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence OXBRYTA’s dominance.
Other emerging products for Sickle cell anaemia are expected to give tough market competition to OXBRYTA and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of OXBRYTA in approved indications.
Analyse OXBRYTA cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
Our in-depth analysis of the forecasted OXBRYTA sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of OXBRYTA in approved indications.
Key Questions
What is the class of therapy, route of administration and mechanism of action of OXBRYTA? How strong is OXBRYTA’s clinical and commercial performance?
What is OXBRYTA’s clinical trial status in each individual indications such as Sickle cell anaemia and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the OXBRYTA Manufacturers?
What are the key designations that have been granted to OXBRYTA for approved indications? How are they going to impact OXBRYTA’s penetration in various geographies?
What is the current and forecasted OXBRYTA market scenario for approved indications? What are the key assumptions behind the forecast?
What are the current and forecasted sales of OXBRYTA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What are the other emerging products available and how are these giving competition to OXBRYTA for approved indications?
Which are the late-stage emerging therapies under development for the treatment of approved indications?
How cost-effective is OXBRYTA? What is the duration of therapy and what are the geographical variations in cost per patient?
Table of Contents
30 Pages
- 1. Report Introduction
- 2. OXBRYTA Overview in approved indications like Sickle cell anaemia
- 2.1. Product Detail
- 2.2. OXBRYTA Clinical Development
- 2.2.1. OXBRYTA Clinical studies
- 2.2.2. OXBRYTA Clinical trials information
- 2.2.3. Safety and efficacy
- 2.3. Other Developmental Activities
- 2.4. Product Profile
- 3. OXBRYTA Competitive Landscape (Marketed Therapies)
- 4. Competitive Landscape (Late-stage Emerging OXBRYTA Therapies)
- 5. OXBRYTA Market Assessment
- 5.1. OXBRYTA Market Outlook in approved indications
- 5.2. 7MM Analysis
- 5.2.1. OXBRYTA Market Size in the 7MM for approved indications
- 5.3. Country-wise Market Analysis
- 5.3.1. OXBRYTA Market Size in the United States for approved indications
- 5.3.2. OXBRYTA Market Size in Germany for approved indications
- 5.3.3. OXBRYTA Market Size in France for approved indications
- 5.3.4. OXBRYTA Market Size in Italy for approved indications
- 5.3.5. OXBRYTA Market Size in Spain for approved indications
- 5.3.6. OXBRYTA Market Size in the United Kingdom for approved indications
- 5.3.7. OXBRYTA Market Size in Japan for approved indications
- 6. OXBRYTA SWOT Analysis
- 7. Analysts’ Views
- 8. Appendix
- 8.1. Bibliography
- 8.2. Report Methodology
- 9. DelveInsight Capabilities
- 10. Disclaimer
- 11. About DelveInsight
- 12. Report Purchase Options
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
